What is Nottingham's Clinical Research Facility planning? Interview with deputy director Prof Chris Fox

Nottingham's long been a leader in researching and treating blood cancer - we pioneered blood stem cell transplantation and we're still one of the biggest centres in the UK. We bring together oncology, clinical haemotology, neuro imaging and surgery and over the last five years we've increased our experimental cancer research trials by 30 percent.

So it's naturally one of the priorities of our new Clinical Research Facility, which recently had its £2.6 million pound funding confirmed by the National Institute for Health and Social Care Research.

The Nottingham facility's team delivers early phase experimental trials not just in cancer, but across the board, including areas such as gastro intestinal disorders, inflammatory conditions, musculoskeletal conditions and respiratory diseases. It's closely integrated with the hospital  and is expanding its inpatient, day beds and out patient facilities, including for children as well as adults.

Its new deputy director is Professor Chris Fox, a consultant haematologist at Nottingham University Hospitals NHS Trust, who has a track record of research into lymphoma and stem cell transplantation, among other things. I spoke to him as he was taking up his new post.

Links

• NIHR Nottingham Clinical Research Facility
• Follow Prof Fox on Twitter
• Cancer research at Nottingham University Hospitals NHS Trust

This Podcast is brought to you by the NIHR Nottingham Biomedical Research Centre. Follow us on @NottmBRC, or email Nottingham research.

If you haven't already, please subscribe to the podcast where-ever you get your podcasts, and like/review us on Apple Podcasts especially. It's For Science.